BridgeBio Pharma, Inc.
BBIO
$36.42
$0.531.48%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -63.57% | -120.59% | -108.59% | 79.06% | 5.00% |
| Total Depreciation and Amortization | -11.12% | -2.29% | -1.38% | 0.69% | -3.29% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 409.18% | 82.05% | -354.20% | 98.75% | -31.43% |
| Change in Net Operating Assets | 704.34% | -100.87% | 209.43% | -1,124.61% | 1,576.51% |
| Cash from Operations | -8.17% | -341.71% | 134.03% | -75.88% | 14.05% |
| Capital Expenditure | 65.69% | -153.70% | 92.23% | -59.77% | -0.93% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 100.00% | 57.14% | -- | -- | -- |
| Other Investing Activities | -108.31% | 1,103.54% | -86.39% | 6,254.47% | -99.03% |
| Cash from Investing | -108.47% | 1,157.85% | -86.64% | 34,574.24% | -100.18% |
| Total Debt Issued | -- | -- | -100.00% | -- | -- |
| Total Debt Repaid | -- | -- | 100.00% | -- | -- |
| Issuance of Common Stock | 32.47% | -- | -- | 95,442.04% | -99.89% |
| Repurchase of Common Stock | 2.70% | 27.74% | 31.98% | -14.91% | 2.11% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | 69.54% | -432.55% | 24.88% |
| Cash from Financing | 66,934.09% | 112.34% | -102.05% | 6,280.59% | -101.47% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 294.42% | -296.68% | -12.99% | 163.96% | -164.87% |